Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-07-06

Reporting Person: Stalfort John A III (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-06	Common Stock	C	130180	—	Acquired	137324	Direct
2021-07-06	Common Stock	P	35000	$16.00	Acquired	172324	Direct
2021-07-06	Common Stock	C	131595	—	Acquired	131595	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-06	Series A-1 Preferred	$	C	130180	Disposed		Common Stock (130180)	Direct
2021-07-06	Series B Preferred	$	C	131595	Disposed		Common Stock (131595)	Indirect

Footnotes

F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of
October 25, 2018.